Haihan Song
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Haihan Song has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Hangxiang Wang
NHC Key Laboratory of Combined Multi-Organ Transplantation, Institute of Organ Transplantation of Zhejiang University, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang Province, Hangzhou 310003, PR China; Jinan Microecological Biomedicine Shandong Laboratory, Jinan, Shandong Province 250117, PR China
4 shared publications - Jian Wan
Emergency and Critical Care Medicine, Shanghai Pudong New Area People's Hospital, 201299 Shanghai, China
2 shared publications Wenchao Gu
Department of Pulmonary and Critical Care Medicine, Shanghai Pudong New Area People's Hospital, Shanghai 201299, P.R. China
2 shared publicationsYuchen Wang
The First Affiliated Hospital, National Health Commission (NHC) Key Laboratory of Combined Multi-Organ Transplantation, School of Medicine, Zhejiang University
2 shared publications- Baohua Qian
Department of Transfusion Medicine, The First Affiliated Hospital of Naval Medical University, Yangpu District, Shanghai, People’s Republic of China
1 shared publication Binbin Xie
Department of Medical Oncology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, 310003, PR China
1 shared publication
Latest Publications
- 13 July 2026
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 481 (8) , 3919-3932
RPS5 modulates inflammatory response and angiogenesis in coronary heart disease through NF-κB signaling activation
Oxidized low-density lipoprotein (ox-LDL) and inflammation cause endothelial dysfunction in coronary heart disease (CHD). Although ribosomal protein S5 (RPS5) has been linked to cardiovascular disease, the mechanism by which it functions in the endothelium and its relationship to NF-κB signaling remain unknown. RPS5 was chosen as the hub gene for CHD after differential expression analysis was done on the GSE68506 dataset. The human coronary artery endothelial cells (HCAECs) injury model was established by ox-LDL. In vitro experiments were performed to evaluate the changes in RPS5 expression, apoptosis, inflammatory markers, vascular protective factors, cell proliferation, and Endothelial-to-Mesenchymal Transition (EndMT). Combining the dual luciferase reporter gene assay and the NF-κB nuclear translocation immunofluorescence assay, the effect of RPS5 on the NF-κB pathway was evaluated. Seven ribosomal genes (RPL11, RPL8, RPS13, RPS20, RPS3, RPS5, RPS8) were downregulated in coronary artery disease (CAD) samples in the GSE68506 dataset. In vitro, ox-LDL injury similarly reduced RPS5 expression in HCAECs. Functionally, RPS5 knockdown inhibits cell proliferation and enhances apoptosis and EndMT, while RPS5 overexpression has the opposite effect. Mechanistically, RPS5 overexpression diminished NF-κB nuclear accumulation, lowered κB-WT reporter activity, and reduced the phosphorylation levels of IKKα/β, IκBα, and p65. It also reduced pro-inflammatory mediators and decreased VEGF and HSP70. The pathway dependency was confirmed when LPS-induced NF-κB activation reversed these effects. Through the NF-κB signaling pathway, RPS5 plays a crucial role in controlling inflammation, apoptosis, EndMT, and vascular protection factors in injured HCAECs. Endothelial damage in CHD may be treatable by focusing on the RPS5–NF-κB axis.
- 13 July 2026
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 481 (8) , 3919-3932
RPS5 modulates inflammatory response and angiogenesis in coronary heart disease through NF-κB signaling activation
Oxidized low-density lipoprotein (ox-LDL) and inflammation cause endothelial dysfunction in coronary heart disease (CHD). Although ribosomal protein S5 (RPS5) has been linked to cardiovascular disease, the mechanism by which it functions in the endothelium and its relationship to NF-κB signaling remain unknown. RPS5 was chosen as the hub gene for CHD after differential expression analysis was done on the GSE68506 dataset. The human coronary artery endothelial cells (HCAECs) injury model was established by ox-LDL. In vitro experiments were performed to evaluate the changes in RPS5 expression, apoptosis, inflammatory markers, vascular protective factors, cell proliferation, and Endothelial-to-Mesenchymal Transition (EndMT). Combining the dual luciferase reporter gene assay and the NF-κB nuclear translocation immunofluorescence assay, the effect of RPS5 on the NF-κB pathway was evaluated. Seven ribosomal genes (RPL11, RPL8, RPS13, RPS20, RPS3, RPS5, RPS8) were downregulated in coronary artery disease (CAD) samples in the GSE68506 dataset. In vitro, ox-LDL injury similarly reduced RPS5 expression in HCAECs. Functionally, RPS5 knockdown inhibits cell proliferation and enhances apoptosis and EndMT, while RPS5 overexpression has the opposite effect. Mechanistically, RPS5 overexpression diminished NF-κB nuclear accumulation, lowered κB-WT reporter activity, and reduced the phosphorylation levels of IKKα/β, IκBα, and p65. It also reduced pro-inflammatory mediators and decreased VEGF and HSP70. The pathway dependency was confirmed when LPS-induced NF-κB activation reversed these effects. Through the NF-κB signaling pathway, RPS5 plays a crucial role in controlling inflammation, apoptosis, EndMT, and vascular protection factors in injured HCAECs. Endothelial damage in CHD may be treatable by focusing on the RPS5–NF-κB axis.
- Open Access
- 20 June 2025
- Published by Spandidos Publications in Molecular and Clinical Oncology
- Vol. 23 (2) , 1-14
Nuclear factor IA‑mediated transcriptional regulation of crystallin αB inhibits hepatocellular carcinoma progression
Hepatocellular carcinoma (HCC) is a highly invasive malignant tumor with limited therapeutic options. In the present study, bioinformatics analysis, including differential expression analysis, functional enrichment, protein‑protein interaction network construction, survival analysis and risk model evaluation, identified CRYAB as a central prognostic gene in HCC. Additionally, motif analysis using JASPAR revealed nuclear factor IA (NFIA), as a potential transcriptional regulator of CRYAB. Further in vitro experiments were conducted to explore the roles of CRYAB and NFIA in HCC, suggesting that these molecules may serve as promising therapeutic targets for future research. Differentially expressed genes (DEGs) from the Cancer Genome Atlas‑liver hepatocellular carcinoma (LIHC) and GSE113996 datasets were identified using the ‘limma’ package, with Biological Process and Kyoto Encyclopedia of Genes and Genomes enrichment analysis conducted. Overlapping DEGs underwent Protein‑protein interaction and prognostic analysis. Key prognostic genes were selected through Kaplan‑Meier survival analysis and Least Absolute Shrinkage and Selection Operator regression before they were incorporated into a predictive risk model, which was evaluated by receiver operating characteristic analysis. JASPAR motif analysis identified NFIA as a potential transcriptional regulator of CRYAB, with the TIMER database used to further examine the NFIA expression profile among other cancers. In vitro assays using MHCC97H and Huh7 cells were used to examine the roles of CRYAB and NFIA in HCC. Cell counting kit‑8 (CCK‑8) assay was used to assess proliferation, whilst Transwell assay was used to measure migration and invasion. To investigate the reciprocal regulation, rescue experiments combining NFIA overexpression and CRYAB knockdown were performed to compare their effects on cell proliferation, migration and invasion. Additionally, dual‑luciferase assay was used to examine the regulatory effect of NFIA on the CRYAB promoter by comparing the wild‑type and mutant constructs. Bioinformatics analyses revealed CRYAB to be a hub gene. CRYAB upregulation was found to be associated with poor prognosis in patients with LIHC. In vitro, elevated CRYAB expression was observed in HCC cell lines compared with that in the huma liver immortalized cell line THLE‑2. CRYAB knockdown was found to significantly inhibit MHCC97H and Huh7 cell proliferation, migration and invasion. By contrast, NFIA expression was found to be downregulated in LIHC compared with that in normal liver tissues, where its expression showed an inverse association with that of CRYAB. Direct interaction between NFIA and the CRYAB promoter region was confirmed through dual‑luciferase assays. Furthermore, low NFIA expression markedly enhanced HCC cell proliferation, invasion and migration. This pro‑tumor effect was reversed in the si‑NFIA + si‑CRYAB group, where simultaneous downregulation of CRYAB significantly reduced cell proliferation, migration and invasion, suggesting that CRYAB downregulation can counteract the effects induced by low NFIA expression. To conclude, these results suggest that NFIA can inhibit the malignant proliferation of HCC cells by activating CRYAB expression, which further suggest that CRYAB and NFIA are promising avenues for the development of novel HCC treatment strategies.
- 20 June 2025
- Published by Spandidos Publications in Molecular and Clinical Oncology
- Vol. 23 (2) , 1-14
Open AccessNuclear factor IA‑mediated transcriptional regulation of crystallin αB inhibits hepatocellular carcinoma progression
Hepatocellular carcinoma (HCC) is a highly invasive malignant tumor with limited therapeutic options. In the present study, bioinformatics analysis, including differential expression analysis, functional enrichment, protein‑protein interaction network construction, survival analysis and risk model evaluation, identified CRYAB as a central prognostic gene in HCC. Additionally, motif analysis using JASPAR revealed nuclear factor IA (NFIA), as a potential transcriptional regulator of CRYAB. Further in vitro experiments were conducted to explore the roles of CRYAB and NFIA in HCC, suggesting that these molecules may serve as promising therapeutic targets for future research. Differentially expressed genes (DEGs) from the Cancer Genome Atlas‑liver hepatocellular carcinoma (LIHC) and GSE113996 datasets were identified using the ‘limma’ package, with Biological Process and Kyoto Encyclopedia of Genes and Genomes enrichment analysis conducted. Overlapping DEGs underwent Protein‑protein interaction and prognostic analysis. Key prognostic genes were selected through Kaplan‑Meier survival analysis and Least Absolute Shrinkage and Selection Operator regression before they were incorporated into a predictive risk model, which was evaluated by receiver operating characteristic analysis. JASPAR motif analysis identified NFIA as a potential transcriptional regulator of CRYAB, with the TIMER database used to further examine the NFIA expression profile among other cancers. In vitro assays using MHCC97H and Huh7 cells were used to examine the roles of CRYAB and NFIA in HCC. Cell counting kit‑8 (CCK‑8) assay was used to assess proliferation, whilst Transwell assay was used to measure migration and invasion. To investigate the reciprocal regulation, rescue experiments combining NFIA overexpression and CRYAB knockdown were performed to compare their effects on cell proliferation, migration and invasion. Additionally, dual‑luciferase assay was used to examine the regulatory effect of NFIA on the CRYAB promoter by comparing the wild‑type and mutant constructs. Bioinformatics analyses revealed CRYAB to be a hub gene. CRYAB upregulation was found to be associated with poor prognosis in patients with LIHC. In vitro, elevated CRYAB expression was observed in HCC cell lines compared with that in the huma liver immortalized cell line THLE‑2. CRYAB knockdown was found to significantly inhibit MHCC97H and Huh7 cell proliferation, migration and invasion. By contrast, NFIA expression was found to be downregulated in LIHC compared with that in normal liver tissues, where its expression showed an inverse association with that of CRYAB. Direct interaction between NFIA and the CRYAB promoter region was confirmed through dual‑luciferase assays. Furthermore, low NFIA expression markedly enhanced HCC cell proliferation, invasion and migration. This pro‑tumor effect was reversed in the si‑NFIA + si‑CRYAB group, where simultaneous downregulation of CRYAB significantly reduced cell proliferation, migration and invasion, suggesting that CRYAB downregulation can counteract the effects induced by low NFIA expression. To conclude, these results suggest that NFIA can inhibit the malignant proliferation of HCC cells by activating CRYAB expression, which further suggest that CRYAB and NFIA are promising avenues for the development of novel HCC treatment strategies.
- Open Access
Burden of renal anemia in 204 countries and territories, 1990-2021 : results from the Global Burden of Disease Study 2021
Background Renal anemia, one of the causes of anemia, has inflicted a certain degree of loss on global health. However, there are no comprehensive analyses on the burden of renal anemia yet. This study aims to comprehensively evaluate the age-standardized prevalence and Years Lived with Disability (YLDs) burden and trends of renal anemia across different sexes, ages, countries, and regions from 1990 to 2021. Methods We analyzed the prevalence and YLDs of renal anemia from 1990 to 2021 across different sexes, ages, countries, and regions. We also examined the relationship between the burden of renal anemia in various regions and the Human Development Index (HDI). Further analyses included the changes in the rank of renal anemia among causes of anemia from 1990 to 2021. Finally, we conducted health inequality analysis, frontier analysis, and APC (age-period-cohort) model analysis on the burden of renal anemia. Results In 2021, the global prevalence of renal anemia across all age groups was 0.82% (95% uncertainty interval [UI] 0.73 - 0.91), equivalent to 63.92 million (59.61 - 71.81) prevalent cases, resulting in 1.70 million (1.13 - 2.43) years lived with disability (YLDs), showing an increase compared to 1990. In recent years, renal anemia has risen in rank among causes of anemia. The burden of renal anemia varies significantly across different age groups and regions, with particularly severe burdens observed among populations over sixty years of age in Central Europe, Eastern Europe, Central Asia, South Asia, Southeast Asia, southern Latin America, and North American countries. A series of analyses based on the HDI revealed the following: descriptive analysis indicated a positive correlation between the prevalence of renal anemia and HDI; cross-national inequality analysis showed an increasing disparity in prevalence and YLDs between high HDI and low HDI countries, with higher burdens in high HDI countries; although with low prevalence, frontier analysis revealed considerable opportunities to reduce the age-standardized YLDs in the Low and medium of HDI spectrum; APC analysis suggested significant differences in the prevalence of renal anemia in high HDI regions (not very high HDI regions) compared to middle and low HDI regions across age, period, and cohort analyses. Conclusions Although the global burden of anemia is decreasing, renal anemia remains a significant health issue, especially among older populations in mid and high-development countries. Targeted programs should be implemented, starting with enhancing diagnosis and treatment in specific regions and populations. The development of new medications should also be considered.
Open AccessBurden of renal anemia in 204 countries and territories, 1990-2021 : results from the Global Burden of Disease Study 2021
Background Renal anemia, one of the causes of anemia, has inflicted a certain degree of loss on global health. However, there are no comprehensive analyses on the burden of renal anemia yet. This study aims to comprehensively evaluate the age-standardized prevalence and Years Lived with Disability (YLDs) burden and trends of renal anemia across different sexes, ages, countries, and regions from 1990 to 2021. Methods We analyzed the prevalence and YLDs of renal anemia from 1990 to 2021 across different sexes, ages, countries, and regions. We also examined the relationship between the burden of renal anemia in various regions and the Human Development Index (HDI). Further analyses included the changes in the rank of renal anemia among causes of anemia from 1990 to 2021. Finally, we conducted health inequality analysis, frontier analysis, and APC (age-period-cohort) model analysis on the burden of renal anemia. Results In 2021, the global prevalence of renal anemia across all age groups was 0.82% (95% uncertainty interval [UI] 0.73 - 0.91), equivalent to 63.92 million (59.61 - 71.81) prevalent cases, resulting in 1.70 million (1.13 - 2.43) years lived with disability (YLDs), showing an increase compared to 1990. In recent years, renal anemia has risen in rank among causes of anemia. The burden of renal anemia varies significantly across different age groups and regions, with particularly severe burdens observed among populations over sixty years of age in Central Europe, Eastern Europe, Central Asia, South Asia, Southeast Asia, southern Latin America, and North American countries. A series of analyses based on the HDI revealed the following: descriptive analysis indicated a positive correlation between the prevalence of renal anemia and HDI; cross-national inequality analysis showed an increasing disparity in prevalence and YLDs between high HDI and low HDI countries, with higher burdens in high HDI countries; although with low prevalence, frontier analysis revealed considerable opportunities to reduce the age-standardized YLDs in the Low and medium of HDI spectrum; APC analysis suggested significant differences in the prevalence of renal anemia in high HDI regions (not very high HDI regions) compared to middle and low HDI regions across age, period, and cohort analyses. Conclusions Although the global burden of anemia is decreasing, renal anemia remains a significant health issue, especially among older populations in mid and high-development countries. Targeted programs should be implemented, starting with enhancing diagnosis and treatment in specific regions and populations. The development of new medications should also be considered.
- 3 August 2023
- Published by Elsevier in Microbial Pathogenesis
- Vol. 183, 106272
Dysregulation of Ruminococcaceae and Megamonas could be predictive markers for rapid progression of mild cognitive impairment
- 3 August 2023
- Published by Elsevier in Microbial Pathogenesis
- Vol. 183, 106272
Dysregulation of Ruminococcaceae and Megamonas could be predictive markers for rapid progression of mild cognitive impairment
- Open Access
- 21 March 2023
- Published by Springer Nature in Research Square
A Novel Prognostic Signature for Combined T-cell Exhaustion and Mitochondrial Dysfunction in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is a common lethal gastrointestinal cancer worldwide. Despite the involvement of T-cell exhaustion and mitochondrial dysfunction in HCC progression, there are no reliable biomarkers for these processes. In this study, we aimed to develop a gene signature that combines T-cell exhaustion- and mitochondrial dysfunction (TEMD)-related genes to predict HCC prognosis and direct immunotherapy and chemotherapy. Data of 240 and 370 patients were obtained from the International Cancer Genome Consortium database as well as the Cancer Genome Atlas, respectively. Using the R package Consensus ClusterPlus, TEMD-high and -low subtypes were generated based on the differential expression of TEMD-related genes and univariate Cox analysis. A two-gene prognostic signature comprising EZH2 and G6PD was constructed and regarded as an independent predictor of outcome. The TEMD high-risk group had a worse overall survival, higher immune infiltration levels, and higher expression of human leukocyte antigen and immune checkpoints. Tumor stemness indices, immunophenoscores, tumor immune dysfunction and exclusion scores, and half-maximal inhibitory concentrations were also compared for TEMD-based molecular subtypes and risk signature. Furthermore, stratification, nomogram construction, gene set enrichment analysis, and small-molecule drug response prediction were performed based on the TEMD-risk signature. Collectively, the proposed two-gene prognostic signature may help determine HCC prognosis and design individualized treatments.
- 21 March 2023
- Published by Springer Nature in Research Square
Open AccessA Novel Prognostic Signature for Combined T-cell Exhaustion and Mitochondrial Dysfunction in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is a common lethal gastrointestinal cancer worldwide. Despite the involvement of T-cell exhaustion and mitochondrial dysfunction in HCC progression, there are no reliable biomarkers for these processes. In this study, we aimed to develop a gene signature that combines T-cell exhaustion- and mitochondrial dysfunction (TEMD)-related genes to predict HCC prognosis and direct immunotherapy and chemotherapy. Data of 240 and 370 patients were obtained from the International Cancer Genome Consortium database as well as the Cancer Genome Atlas, respectively. Using the R package Consensus ClusterPlus, TEMD-high and -low subtypes were generated based on the differential expression of TEMD-related genes and univariate Cox analysis. A two-gene prognostic signature comprising EZH2 and G6PD was constructed and regarded as an independent predictor of outcome. The TEMD high-risk group had a worse overall survival, higher immune infiltration levels, and higher expression of human leukocyte antigen and immune checkpoints. Tumor stemness indices, immunophenoscores, tumor immune dysfunction and exclusion scores, and half-maximal inhibitory concentrations were also compared for TEMD-based molecular subtypes and risk signature. Furthermore, stratification, nomogram construction, gene set enrichment analysis, and small-molecule drug response prediction were performed based on the TEMD-risk signature. Collectively, the proposed two-gene prognostic signature may help determine HCC prognosis and design individualized treatments.
- Open Access
- 2 March 2023
- Published by Taylor & Francis in Drug Delivery
- Vol. 30 (1) , 2183821
Oral liposomal delivery of an activatable budesonide prodrug reduces colitis in experimental mice
Inflammatory bowel disease (IBD) is one of the most common intestinal disorders, with increasing global incidence and prevalence. Numerous therapeutic drugs are available but require intravenous administration and are associated with high toxicity and insufficient patient compliance. Here, an oral liposome that entraps the activatable corticosteroid anti-inflammatory budesonide was developed for efficacious and safe IBD therapy. The prodrug was produced via the ligation of budesonide with linoleic acid linked by a hydrolytic ester bond, which was further constrained into lipid constituents to form colloidal stable nanoliposomes (termed budsomes). Chemical modification with linoleic acid augmented the compatibility and miscibility of the resulting prodrug in lipid bilayers to provide protection from the harsh environment of the gastrointestinal tract, while liposomal nanoformulation enables preferential accumulation to inflamed vasculature. Hence, when delivered orally, budsomes exhibited high stability with low drug release in the stomach in the presence of ultra-acidic pH but released active budesonide after accumulation in inflamed intestinal tissues. Notably, oral administration of budsomes demonstrated favorable anti-colitis effect with only ∼7% mouse body weight loss, whereas at least ∼16% weight loss was observed in other treatment groups. Overall, budsomes exhibited higher therapeutic efficiency than free budesonide treatment and potently induced remission of acute colitis without any adverse side effects. These data suggest a new and reliable approach for improving the efficacy of budesonide. Our in vivo preclinical data demonstrate the safety and increased efficacy of the budsome platform for IBD treatment, further supporting clinical evaluation of this orally efficacious budesonide therapeutic.
- 2 March 2023
- Published by Taylor & Francis in Drug Delivery
- Vol. 30 (1) , 2183821
Open AccessOral liposomal delivery of an activatable budesonide prodrug reduces colitis in experimental mice
Inflammatory bowel disease (IBD) is one of the most common intestinal disorders, with increasing global incidence and prevalence. Numerous therapeutic drugs are available but require intravenous administration and are associated with high toxicity and insufficient patient compliance. Here, an oral liposome that entraps the activatable corticosteroid anti-inflammatory budesonide was developed for efficacious and safe IBD therapy. The prodrug was produced via the ligation of budesonide with linoleic acid linked by a hydrolytic ester bond, which was further constrained into lipid constituents to form colloidal stable nanoliposomes (termed budsomes). Chemical modification with linoleic acid augmented the compatibility and miscibility of the resulting prodrug in lipid bilayers to provide protection from the harsh environment of the gastrointestinal tract, while liposomal nanoformulation enables preferential accumulation to inflamed vasculature. Hence, when delivered orally, budsomes exhibited high stability with low drug release in the stomach in the presence of ultra-acidic pH but released active budesonide after accumulation in inflamed intestinal tissues. Notably, oral administration of budsomes demonstrated favorable anti-colitis effect with only ∼7% mouse body weight loss, whereas at least ∼16% weight loss was observed in other treatment groups. Overall, budsomes exhibited higher therapeutic efficiency than free budesonide treatment and potently induced remission of acute colitis without any adverse side effects. These data suggest a new and reliable approach for improving the efficacy of budesonide. Our in vivo preclinical data demonstrate the safety and increased efficacy of the budsome platform for IBD treatment, further supporting clinical evaluation of this orally efficacious budesonide therapeutic.
- Open Access
Understanding the Contribution of Lactate Metabolism in Cancer Progress: A Perspective from Isomers
Lactate mediates multiple cell-intrinsic effects in cancer metabolism in terms of development, maintenance, and metastasis and is often correlated with poor prognosis. Its functions are undertaken as an energy source for neighboring carcinoma cells and serve as a lactormone for oncogenic signaling pathways. Indeed, two isomers of lactate are produced in the Warburg effect: L-lactate and D-lactate. L-lactate is the main end-production of glycolytic fermentation which catalyzes glucose, and tiny D-lactate is fabricated through the glyoxalase system. Their production inevitably affects cancer development and therapy. Here, we systematically review the mechanisms of lactate isomers production, and highlight emerging evidence of the carcinogenic biological effects of lactate and its isomers in cancer. Accordingly, therapy that targets lactate and its metabolism is a promising approach for anticancer treatment.
Open AccessUnderstanding the Contribution of Lactate Metabolism in Cancer Progress: A Perspective from Isomers
Lactate mediates multiple cell-intrinsic effects in cancer metabolism in terms of development, maintenance, and metastasis and is often correlated with poor prognosis. Its functions are undertaken as an energy source for neighboring carcinoma cells and serve as a lactormone for oncogenic signaling pathways. Indeed, two isomers of lactate are produced in the Warburg effect: L-lactate and D-lactate. L-lactate is the main end-production of glycolytic fermentation which catalyzes glucose, and tiny D-lactate is fabricated through the glyoxalase system. Their production inevitably affects cancer development and therapy. Here, we systematically review the mechanisms of lactate isomers production, and highlight emerging evidence of the carcinogenic biological effects of lactate and its isomers in cancer. Accordingly, therapy that targets lactate and its metabolism is a promising approach for anticancer treatment.
- Open Access
- 31 January 2022
- Published by American Association for the Advancement of Science (AAAS) in Biomaterials Research
- Vol. 26 (1) , 1-18
Combinatorial nanococktails via self-assembling lipid prodrugs for synergistically overcoming drug resistance and effective cancer therapy
Background: Combinatorial systemic chemotherapy is a powerful treatment paradigm against cancer, but it is fraught with problems due to the emergence of chemoresistance and additive systemic toxicity. In addition, coadministration of individual drugs suffers from uncontrollable pharmacokinetics and biodistribution, resulting in suboptimal combination synergy. Methods: Toward the goal of addressing these unmet medical issues, we describe a unique strategy to integrate multiple structurally disparate drugs into a self-assembling nanococktail platform. Conjugation of a polyunsaturated fatty acid (e.g., linoleic acid) with two chemotherapies generated prodrug entities that were miscible with tunable drug ratios for aqueous self-assembly. In vitro and in vivo assays were performed to investigate the mechanism of combinatorial nanococktails in mitigating chemoresistance and the efficacy of nanotherapy. Results: The coassembled nanoparticle cocktails were feasibly fabricated and further refined with an amphiphilic matrix to form a systemically injectable and PEGylated nanomedicine with minimal excipients. The drug ratio incorporated into the nanococktails was optimized and carefully examined in lung cancer cells to maximize therapeutic synergy. Mechanistically, subjugated resistance by nanococktail therapy was achieved through the altered cellular uptake pathway and compromised DNA repair via the ATM/Chk2/p53 cascade. In mice harboring cisplatin-resistant lung tumor xenografts, administration of the nanococktail outperformed free drug combinations in terms of antitumor efficacy and drug tolerability. Conclusion: Overall, our study provides a facile and cost-effective approach for the generation of cytotoxic nanoparticles to synergistically treat chemoresistant cancers.
- 31 January 2022
- Published by American Association for the Advancement of Science (AAAS) in Biomaterials Research
- Vol. 26 (1) , 1-18
Open AccessCombinatorial nanococktails via self-assembling lipid prodrugs for synergistically overcoming drug resistance and effective cancer therapy
Background: Combinatorial systemic chemotherapy is a powerful treatment paradigm against cancer, but it is fraught with problems due to the emergence of chemoresistance and additive systemic toxicity. In addition, coadministration of individual drugs suffers from uncontrollable pharmacokinetics and biodistribution, resulting in suboptimal combination synergy. Methods: Toward the goal of addressing these unmet medical issues, we describe a unique strategy to integrate multiple structurally disparate drugs into a self-assembling nanococktail platform. Conjugation of a polyunsaturated fatty acid (e.g., linoleic acid) with two chemotherapies generated prodrug entities that were miscible with tunable drug ratios for aqueous self-assembly. In vitro and in vivo assays were performed to investigate the mechanism of combinatorial nanococktails in mitigating chemoresistance and the efficacy of nanotherapy. Results: The coassembled nanoparticle cocktails were feasibly fabricated and further refined with an amphiphilic matrix to form a systemically injectable and PEGylated nanomedicine with minimal excipients. The drug ratio incorporated into the nanococktails was optimized and carefully examined in lung cancer cells to maximize therapeutic synergy. Mechanistically, subjugated resistance by nanococktail therapy was achieved through the altered cellular uptake pathway and compromised DNA repair via the ATM/Chk2/p53 cascade. In mice harboring cisplatin-resistant lung tumor xenografts, administration of the nanococktail outperformed free drug combinations in terms of antitumor efficacy and drug tolerability. Conclusion: Overall, our study provides a facile and cost-effective approach for the generation of cytotoxic nanoparticles to synergistically treat chemoresistant cancers.
- Open Access
- 1 January 2021
- Published by Ivyspring International Publisher in Theranostics
- Vol. 11 (12) , 5713-5727
Quantitative self-assembly of pure drug cocktails as injectable nanomedicines for synergistic drug delivery and cancer therapy
New strategies to fabricate nanomedicines with high translational capacity are urgently desired. Herein, a new class of self-assembled drug cocktails that addresses the multiple challenges of manufacturing clinically useful cancer nanomedicines was reported.
- 1 January 2021
- Published by Ivyspring International Publisher in Theranostics
- Vol. 11 (12) , 5713-5727
Open AccessQuantitative self-assembly of pure drug cocktails as injectable nanomedicines for synergistic drug delivery and cancer therapy
New strategies to fabricate nanomedicines with high translational capacity are urgently desired. Herein, a new class of self-assembled drug cocktails that addresses the multiple challenges of manufacturing clinically useful cancer nanomedicines was reported.